SN-001

HY-W140974
727699-84-5
$C_{26}H_{21}FN_2O_4S$
476.52
STING
Immunology/Inflammation
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

SOLVENT & SOLUBILITY

®

MedChemExpress

In Vitro	DMSO : 250 mg/mL (524.64 mM; Need ultrasonic)					
Preparing Stock Solutions Please refer to the s	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	2.0985 mL	10.4927 mL	20.9855 mL	
	5 mM	0.4197 mL	2.0985 mL	4.1971 mL		
		10 mM	0.2099 mL	1.0493 mL	2.0985 mL	
	Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent Solubility: ≥ 2.08 r	one by one: 10% DMSO >> 90% cor ng/mL (4.36 mM); Clear solution	n oil			

DIOLOGICALACITY				
Description	SN-001 is a STING inhibitor v	with an IC ₅₀ of 3.82 μ M ^[1] .		
IC ₅₀ & Target	IC ₅₀ : 3.82 μM (STING) ^[1]			
In Vitro	SN-001 targets the cyclic dinucleotide binding pocket of human STING ^[1] . SN-001 (5-20 μM; 6 h) significantly impairs the induction of Ifnb mRNA, in a dose-dependent manner in L929 cells ^[1] . SN-001 (10 μM; 3 h) inhibits cytosolic DNA-triggered STING signaling ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis ^[1]			
	Cell Line:	L929 cells		
	Concentration:	10 µM		

Product Data Sheet

0

NH O=S=O

`N´ H

Incubation Time:	3 h
Result:	Decreased cytosolic DNA-induced phosphorylation of STING, TBK1, IRF3, $I\kappa B\alpha$, and p65, a well as nuclear translocation of IRF3 and p65.

REFERENCES

[1]. Hong Z, et al. STING inhibitors target the cyclic dinucleotide binding pocket. Proc Natl Acad Sci U S A. 2021 Jun 15;118(24):e2105465118.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA